

1 *Are Escherichia coli* causing recurrent cystitis just ordinary
2 Uropathogenic *E. coli* (UPEC) strains?

3 Running title: Uropathogenic *Escherichia coli* causing recurrent cystitis are host-adapted

4 Nicolas Vautrin^{1*}, Sandrine Dahyot², Marie Leoz¹, François Caron³, Maxime Grand¹, Audrey
5 Feldmann¹, François Gravey⁴, Stéphanie Legris¹, David Ribet⁵, Kévin Alexandre³, Martine Pestel-
6 Caron²

7 ¹ Univ Rouen Normandie, Université de Caen Normandie, INSERM, Normandie Univ, DYNAMICURE
8 UMR 1311, F-76000 Rouen, France

9 ² Univ Rouen Normandie, Université de Caen Normandie, INSERM, Normandie Univ, DYNAMICURE
10 UMR 1311, CHU Rouen, department of microbiology, F-76000 Rouen, France

11 ³ Univ Rouen Normandie, Université de Caen Normandie, INSERM, Normandie Univ, DYNAMICURE
12 UMR 1311, CHU Rouen, department of infectious diseases, F-76000 Rouen, France

13 ⁴ Université de Caen Normandie, Univ Rouen Normandie, INSERM, Normandie Univ, DYNAMICURE
14 UMR 1311, F-14000 Caen, France

15 ⁵ Univ Rouen Normandie, INSERM, Normandie Univ, ADEN UMR 1073, Nutrition, inflammation and
16 microbiota-gut-brain axis, F-76000 Rouen, France

17

18 *Corresponding author

19 E-mail: vautrin.nicolas@outlook.com

20

21 **Abstract**

22 Specific determinants associated with Uropathogenic *Escherichia coli* (UPEC) causing recurrent cystitis
23 are still poorly characterized. The aims of this study were (i) to describe genomic and phenotypic traits
24 associated with recurrence using a large collection of recurrent and paired sporadic UPEC isolates, and
25 (ii) to explore within-host genomic adaptation associated with recurrence using series of 2 to 5 sequential
26 UPEC isolates. Whole genome comparative analyses between 24 recurrent cystitis isolates (RCIs) and
27 24 phylogenetically paired sporadic cystitis isolates (SCIs) suggested a lower prevalence of putative
28 mobile genetic elements (MGE) in RCIs, such as plasmids and prophages. The intra-patient evolution
29 of the 24 RCI series over time was characterized by SNP occurrence in genes involved in metabolism
30 or membrane transport, and by plasmid loss in 5 out of the 24 RCI series. Genomic evolution occurred
31 early in the course of recurrence, suggesting rapid adaptation to strong selection pressure in the urinary
32 tract.

33 However, RCIs did not exhibit specific virulence factor determinants and could not be distinguished
34 from SCIs by their fitness, biofilm formation, or ability to invade HTB-9 bladder epithelial cells. Taken
35 together, these results suggest a rapid but not convergent adaptation of RCIs that involves both strain-
36 and host-specific characteristics.

37

38 **Author summary**

39 The recurrence of cystitis is a frequent but poorly understood phenomenon. There are currently many
40 hypotheses trying to explain recurrence, but data on large collections of well-characterized clinical
41 isolates are lacking. In order to identify specific recurrence-associated markers, we conducted a large
42 genomic and phenotypic study involving 48 well-characterized cystitis isolates: 24 recurrent cystitis
43 isolates (RCIs) and 24 pairs of isolates causing sporadic cystitis (SCIs). Moreover, we were able to
44 explore intra-host overtime RCI evolution, by analyzing up to 5 sequential UPEC isolates per RCI series.
45 Our results suggest that RCI rapidly adapt to their host through mobile genetic elements loss and SNP
46 accumulation in genes involved in metabolism and membrane transport. However, no convergent
47 genomic nor phenotypic evolution was observed between isolates collected from distinct patients. Taken
48 together, these results suggest a host-shaped evolution of RCIs, highlighting a need for future studies
49 focused on the host-pathogen relationships.

50

51 **Introduction**

52 Urinary tract infections (UTIs) are very common bacterial infections in women as more than half of
53 them will develop at least one UTI during their lifetime [1]. Up to 25% of women who had a UTI will
54 experience a second one within a year [2]. If a woman presents more than 2 episodes within a 6-month
55 period or 3 episodes within 12 months, she will be considered as suffering from recurrent UTI (rUTI)
56 [3]. rUTI is a public health concern, and is associated with an economic, societal, and personal burden.
57 It represents 1% to 6% of all medical visits and is the second leading cause of antibiotic consumption in
58 the United States [2]. Its annual cost is estimated at 1.6 billion US dollars [4]. Moreover, rUTI negatively
59 impacts quality of life, as they promote anxiety and depression [4].

60 rUTIs are mainly caused by uropathogenic *Escherichia coli* (UPEC) [2] whether relapses or reinfections.
61 Relapse is defined by infection with the same strain as the initial infecting strain whereas reinfection
62 corresponds to infection with a strain different from the initial one [5]. Using pulsed-field gel
63 electrophoresis (PGFE), it was previously estimated that 47 to 81% of UPEC rUTI were due to relapses
64 [3]. However, this statement was primarily based on typing methods such as serotyping [6] and pulsed-
65 field gel electrophoresis (PFGE) [5,7,8] which have limited discriminatory power compared to
66 molecular-based methods [9]. Using next generation sequencing (NGS) and CH typing - a molecular
67 typing method based on the polymorphism of internal fragments of two genes (*fumC* and *fimH*) [10],
68 we recently observed that the frequency of relapses was only 30.6% [11].

69 UPEC virulence primarily relies on their ability to survive and grow in urine, as well as to adhere to and
70 invade urothelial cells [12]. Although certain mechanisms involved in UPEC virulence have been well
71 described, the physiopathology of recurrent cystitis remains poorly characterized [13]. Among the
72 existing hypotheses, it has been postulated that the ability of UPECs to persist in the bladder by forming
73 intracellular bacterial communities (IBC) and quiescent intracellular reservoir (QIR) is involved in
74 recurrent cystitis [14–16]. However, this phenomenon has not yet been explored in large cohorts of
75 patients. Moreover, no specific genomic nor phenotypic marker have been identified to distinguish
76 UPECs associated with recurrent cystitis from those causing sporadic cystitis [17–19].

77 In this context, our study first aimed to identify genomic and/or phenotypic determinants associated with
78 recurrence using a collection of 24 recurrent cystitis isolates (RCIs) and 24 phylogenetically paired
79 isolates responsible for sporadic cystitis (SCIs), sampled from patients with clinically well-characterized
80 cystitis over a 17-month period (VITALE study, NTC02292160). The second aim was to describe
81 within-host microevolution of the 24 RCIs over time, by analysing the genomic and phenotypic changes
82 in 24 series of 2 to 5 sequential isolates.

83 **Results**

84 **Analysis of 26 virulence factors determinants did not distinguish** 85 **RCIs from SCIs**

86 To identify genomic traits associated with recurrence, we compared the genomes of 24 initial RCI
87 (iRCIs) with those of 24 SCIs that phylogenetically matched based on CH typing (Fig 1, Table S1). The
88 presence and protein sequence of 26 virulence factor determinants (VFDs) of interest [17] were
89 compared between these two groups (Table 1).

90 The prevalence of the 26 VFDs ranged from 0.0% to 95.8% among the 48 UPEC isolates, with no
91 significant difference between the iRCI and SCI groups. The aggregate VFD score median, determined
92 as previously described by Ejrnaes *et al.* [17], was also not significantly different between the two groups
93 of isolates (median of 9 for iRCIs vs. 10 for SCIs, $p = 0.665$) (Table 1). Moreover, a principal component
94 analysis based on the detection of the 26 VFDs revealed that iRCIs and SCIs did not cluster separately
95 (Fig 2). There were up to 18 alleles identified per gene (*malX*), with no significant association with
96 recurrence (Table 1, Fig S1).

97

98 **Table 1. Prevalence of virulence factors determinants (VFDs) in the 24 iRCIs and 24 SCIs. NA**

99 stands for “non-applicable”.

	Total (n, %)	Total allele number	iRCIs (n = 24)	SCIs (n = 24)	<i>p. value</i> #1	<i>p. value</i> #2
Aggregate VFD score median (range)	10 (2 - 14)	NA	9 (3 - 13)	10.5 (2 - 14)	0.582	NA
Virulence factor determinants count (%)						
Adhesins						
<i>fimH</i>	46 (95.8%)	17	23 (95.8%)	23 (95.8%)	1 [□]	NA
<i>papG</i>	15 (31.3%)	8	7 (29.2%)	8 (33.3%)	1*	0.23*
<i>focD</i>	11 (22.9%)	10	6 (25.0%)	5 (20.8%)	1*	0.45*
<i>iha</i>	10 (20.8%)	4	6 (25.0%)	4 (16.6%)	0.722*	1*
<i>afaE1</i>	2 (4.2%)	1	1 (4.2%)	1 (4.2%)	1 [□]	NA
<i>bmaE</i>	2 (4.2%)	2	1 (4.2%)	1 (4.2%)	1 [□]	1*
<i>focG</i>	1 (2.1%)	1	1 (4.2%)	0 (0.0%)	1 [□]	NA
<i>afaE3</i>	0 (0.0%)	0	0 (0.0%)	0 (0.0%)	NA	NA
<i>draA</i>	0 (0.0%)	0	0 (0.0%)	0 (0.0%)	NA	NA
Biofilm related						
<i>flu</i>	11 (22.9%)	10	3 (12.5%)	8 (33.3%)	0.169*	0.56*
Iron uptake						
<i>fyuA</i>	41 (85.4%)	9	21 (87.5%)	20 (83.3%)	1 [□]	1*
<i>chuA</i>	40 (83.3%)	10	21 (87.5%)	19 (79.2%)	0.700 [□]	0.35*
<i>iroN</i>	28 (58.3%)	13	13 (54.2%)	15 (62.5)	0.770*	0.77*
<i>iutA</i>	23 (47.9%)	7	10 (41.7%)	13 (54.2%)	0.563*	0.94*
<i>ireA</i>	10 (20.8%)	4	6 (25.0%)	4 (16.6%)	0.722*	1*
pUTI89	8 (16.7%)	NA	3 (12.5%)	5 (20.8%)	0.700 [□]	NA
Protectins						
<i>iss</i>	42 (87.5%)	9	21 (87.5%)	21 (87.5%)	1 [□]	1*
<i>traT</i>	36 (75.0%)	11	16 (66.7%)	20 (83.3%)	0.317*	0.09*
<i>kpsM</i>	34 (70.8%)	7	18 (75.0%)	16 (66.7%)	0.751*	0.88*
Toxins						
<i>hlyA</i>	9 (18.8%)	6	3 (12.5%)	6 (25.0%)	0.461 [□]	0.11*
<i>sat</i>	9 (18.8%)	4	5 (20.8%)	4 (16.6%)	1 [□]	0.52*
<i>cnfI</i>	7 (14.6%)	5	5 (20.8%)	2 (8.3%)	0.416 [□]	1*
<i>cdtB</i>	0 (0.0%)	0	0 (0.0%)	0 (0.0%)	NA	NA
Miscellaneous						
<i>malX</i>	43 (89.6%)	18	20 (83.3%)	23 (95.8%)	0.347 [□]	0.71*
<i>ibeA</i>	12 (25.0%)	5	7 (29.2%)	5 (20.8%)	0.739*	0.67*
<i>usp</i>	10 (20.8%)	5	4 (16.6%)	6 (25.0%)	0.722*	0.62*

100

101 #1: H0 hypothesis: There is no difference of gene prevalence between iRCIs and SCIs

102 #2: H0 hypothesis: Alleles distribution among iRCIs and SCIs is identical

103 **p. value* determined using Fisher's exact test for count data

104 [□]*p. value* determined using Pearson's Chi-squared test with Yates' continuity correction

105 Among the 10 adhesin-encoding genes investigated, *fimH* was the most prevalent (95.8%) (Table 1).
106 We did not test the association of the 17 *fimH* alleles with clinical context since this gene belongs to the
107 typing scheme used to pair SCIs to the 24 iRCIs. The second most common gene in this virulence group
108 was *papG* (31.3%). Two of the four previously described *papG* variants [20,21] were identified (*papGII*
109 and *papGIII*), although they were not significantly associated with the RCI or SCI groups.

110 The most prevalent markers associated with iron uptake were *fyuA* (85.4%) and *chuA* (83.3%), while
111 the least frequent was pUTI89, a plasmid associated with iron uptake [22]. The great majority of the
112 isolates (41/48, 85.4%) presented at least two iron uptake genes. Three isolates (one iRCI/SCI pair and
113 one SCI) were negative for all iron uptake markers tested.

114 The global prevalence of toxin-encoding genes (*hlyA*, *sat*, *cnf1*, *cdtB*) and of the *flu* gene associated with
115 biofilm production was low (<25%), while the prevalence of genes encoding protectins was high
116 (>70%).

117 **iRCI genomes were significantly smaller than phylogenetically** 118 **paired SCIs**

119 The mean genome size of iRCIs was significantly lower than that of SCIs (5.01 Mb vs. 5.11 Mb,
120 respectively, $p < 0.05$), resulting in a significantly lower mean protein count (4,658 vs. 4,776 in iRCIs
121 vs. SCIs, respectively, $p < 0.05$). The pan-genome of the 48 assemblies contained 15,682 genes, of which
122 2,864 (18.3%) were considered core genes. Phylogenetic analysis of the core genes confirmed that
123 isolates clustered based on CH type rather than on the sporadic/recurrent clinical context (Fig 3A),
124 consistent with the SCI/iRCI CH type-based pairing strategy.

125 A genome-wide association study (GWAS) was performed based on the presence or absence of
126 accessory genes in iRCIs vs. SCIs (Fig 3C). Only two genes were significantly less frequent in RCI
127 genomes (Sgene1, $p = 0.009$ and Sgene2, $p = 0.009$). Proteins encoded by these genes were annotated
128 as phage-associated proteins by InterProScan. Sgene1 encoded an unknown DNA binding protein with
129 a helix turn helix domain (LocusTag OMANCKEL_0742 in CS2737) and Sgene 2 encoded a regulatory
130 phage protein from the Cox family (LocusTag OMANCKEL_0743 in CS2737; InterPro entry:
131 IPR019679). In the 7 SCIs where Sgene1 and Sgene2 were identified, they were located back-to-back

132 and followed by a sequence of up to 40 hypothetical proteins-coding genes, most of which being
133 annotated as phage-associated proteins by InterProScan. This putative prophage was located between
134 the *cpx* operon and the *fieF* gene (also named *yiiP*), encoding an envelope stress response system and a
135 ferrous iron efflux pump, respectively.

136 Systematic Phigaro analysis of the 48 draft genomes confirmed the presence of diverse phage sequences
137 inserted between the *cpx* operon and *fieF* gene of 8 SCIs, but in only 2 of their paired iRCIs (Fig 3B).

138 iRCI reads were mapped to their paired SCI assembly to illustrate the phage presence/absence (Fig 4A).

139 This analysis also highlighted that some very large SCI contigs (up to 40 kb) were absent in paired iRCI;
140 some of these contigs contained genes from the *tra* operon, which suggested that they derived from
141 plasmids (Fig 4B).

142 Taken together, these results suggested that mobile genetic elements (MGEs) were less frequent in iRCIs
143 than in SCIs, consistent with their lower genome sizes.

144 **Longitudinally sampled RCIs lost plasmids over the course of** 145 **relapses**

146 Long-read whole genome sequencing and hybrid assemblies were performed on the 24 iRCIs
147 investigated so far in order to better describe their genomes and in particular their plasmids. Hybrid
148 assembly reduced by 19-fold the mean number of contigs per genome and modestly increased the total
149 genome size (mean of 5.10 Mb instead of 5.01 Mb), though mean estimated completeness remained
150 99.9% for hybrid as well as short read assemblies according to BUSCO.

151 To longitudinally investigate RCI evolution over time, short reads from each recurrent cystitis isolate
152 associated with relapse(s) (rRCI, one to four relapses per patient) were mapped to the hybrid assembly
153 of their iRCI, used as an intra-host reference. Interestingly, 5 of the 24 RCIs (21%) lost up to 3 circular
154 contigs over the course of relapses, identified as plasmids using blast. Of the 8 lost plasmids, 4 were
155 small cryptical plasmids (<5kb) coding only hypothetical proteins (Table S2). The three others were
156 large plasmids (>40kb) encoding conjugation system (*tra* operon), toxin-antitoxins systems, and a few

157 proteins that could not be associated with urovirulence. In 7 cases out of 8, plasmid loss occurred
158 between the iRCI and the first rRCI (exemplified in Fig 4C).

159 **Non-synonymous SNPs of longitudinally sampled RCIs often** 160 **occurred in genes involved in metabolism and membrane transport**

161 To investigate RCI micro-evolution, we looked for SNP acquisition over time. In the 24 relapse series,
162 a total of 666 SNPs were identified. Among these, 255 (38.3%) were non-synonymous SNPs (nsSNPs).
163 Functional annotation of the 160 proteins affected by these nsSNPs was successful for 107 proteins, 58
164 of which were mapped in defined biological processes by blastKoala (Table 2). These 58 proteins were
165 mostly involved in diverse metabolic pathways ($n = 22$, 37.9%) and membrane transport ($n = 12$, 20.7%).

166 Notably, 10 out of the 24 RCIs acquired nsSNPs in genes encoding diverse ABC membrane transporters.
167 Among these, two were involved in metal ion transport (nickel import ATP-binding protein NikD,
168 LocusTag = OKMJCHAP_00349 in iRCI_2002; and Fe(3+) dicitrate transport system permease protein
169 FecC, LocusTag = AHEJCLJF_03297 in iRCI_2110). One membrane transport protein
170 (lipopolysaccharide export system ATP-binding protein LptB) acquired nsSNPs in two distinct relapse
171 series (LocusTag = MMGADFLO_03138 in iRCI_2229 and HFPIPPMJ_01315 in iRCI_2359). Of note,
172 another nsSNP occurred in a gene involved in lipopolysaccharide biosynthesis (lipid A export ATP-
173 binding/permease protein MsbA, LocusTag = AKCFODAC_00517 in iRCI_2484).

174

175 **Table 2. Functional classification of the 58 proteins encoded by genes in which non-synonymous**
 176 **SNPs have occurred overtime in the RCI series.** Annotation and corresponding biological process
 177 were provided by BlastKoala. Of note, a single gene can be involved in several biological processes.

Functionnal category	Number of genes
Metabolism	(n = 22 genes)
Global and overview maps	17
Diverses metabolic pathways	16
Biosynthesis of secondary metabolites	9
Microbial metabolism in diverse environnements	4
Carbon metabolism	2
Biosynthesis of amino acids	1
Biosynthesis of nucleotide sugars	1
Biosynthesis of cofactors	3
Biosynthesis of aromatic compounds	1
Carbohydrate metabolism	5
Glycolysis / Gluconeogenesis	1
Citrate cycle (TCA cycle)	1
Pentose and glucuronate interconversions	1
Fructose and mannose metabolism	1
Amino sugar and nucleotide sugar metabolism	1
Pyruvate metabolism	2
Propanoate metabolism	2
Butanoate metabolism	1
C5-Branched dibasic acid metabolism	1
Energy metabolism	2
Carbon fixation pathways	2
Methane metabolism	1
Lipid metabolism	1
Fatty acid degradation	1
Nucleotide metabolism	1
Purine metabolism	1
Amino acids metabolism	5
Glycine, serine and threonine metabolism	1
Lysine degradation	1
Arginine and proline metabolism	1
Histidine metabolism	1
Tyrosine metabolism	1
Metabolism of other amino acids	2
Taurine and hypotaurine metabolism	1
Gluthathione metabolism	1
Glycan biosynthesis and metabolism	5
Lipopolysaccharide biosynthesis	4
Exopolysaccharide biosynthesis	1

Metabolism of cofactors and vitamins	3
Biotin metabolism	1
Porphyrin metabolism	1
Ubiquinone and other terpenoid-quinones biosynthesis	1
Metabolism of terpenoids and polyketides	1
Biosynthesis of siderophore group nonribosomal peptides	1
Biosynthesis of other secondary metabolites	1
Tropane, piperidine and pyridine alkaloid biosynthesis	1
Xenobiotics biodegradation and metabolism	4
Chloroalkane and chloroalkene degradation	1
Naphthalene degradation	1
Metabolism of xenobiotics by cytochrome P450	1
Drug metabolism - cytochrome P450	1
Drug metabolism - other enzymes	1
Environnemental information processing	(n = 15 genes)
Membrane transport	11
ABC transporters	10
Bacterial secretion systems	1
Signal transduction	3
Two-component system	3
Genetic information processing	(n = 6 genes)
Translation	2
Ribosome	1
Aminoacyl-tRNA biosynthesis	1
Folding, sorting and degradation	3
RNA degradation	3
Replication and repair	4
DNA replication	2
Base excision repair	1
Mismatch repair	2
Homologous recombination	3
Cellular processes	(n = 6 genes)
Cellular community – prokaryotes	5
Quorum sensing	2
Biofilm formation – <i>Vibrio cholerae</i>	2
Biofilm formation – <i>Escherichia coli</i>	2
Cell motility	1
Flagellar assembly	1
Human diseases	(n = 5 genes)
Cancer: overview	1
Pathways in cancer	1
Chemical carcinogenesis – DNA adducts	1
Chemical carcinogenesis – receptor activation	1
Chemical carcinogenesis – reactive oxygen species	1
Cancer: specific types	1

Hepatocellular carcinoma	1
Infectious disease: bacterial	1
Shigellosis	1
Yersinia infection	1
Pertussis	2
Bacterial invasion of epithelial cells	1
Infectious disease: parasitic	1
Amoebiasis	1
Cardiovascular disease	1
Fluid shear and atherosclerosis	1
Drug resistance: antineoplastic	1
Platinum drug resistance	1
Organismal systems	(n = 1 gene)
Aging	1
Longevity regulating pathway – worm	1

178 Overtime conserved SNPs were investigated in the 7 RCI series that contained more than 2 episodes. A
 179 total of 13 SNPs identified in the first rRCI were conserved in the following ones. Ten of these overtime
 180 conserved SNPs occurred in ORFs and 6 of these were non synonymous. Of note, two genes that
 181 acquired conserved nsSNPs were involved in membrane transport according to Prokka: an ABC
 182 transporter (Inner membrane ABC transporter permease protein YdcV, LocusTag =
 183 KNBHMFIB_00972 in iRCI_2287) and a permease involved into peptide transport (Dipeptide and
 184 tripeptide permease A, LocusTag = MMGADFLO_01450 in iRCI_2229). Other genes affected by
 185 overtime-conserved nsSNPs encoded ribonucleases and a sigma-E factor regulatory protein (Table S3).

186 **RCI genomic evolution rate tended to decrease overtime**

187 Evolution rates between each rRCI and its corresponding iRCI ranged from 0 to 1.67 SNPs/day (mean
 188 of 0.27 SNP/day). Evolution rates tended to decrease over time, even if this trend was not significant (p
 189 = 0.124) (Fig 5A). However, an outlier (circled in red on Fig 5A) acquired 378 SNPs over a long period
 190 (226 days), 93% of which SNPs were located in only two plasmid-derived contigs. In depth comparison
 191 of the iRCI and rRCI contigs from this outlier suggested that these SNPs were artifacts due to the
 192 comparison of similar regions that derived from different plasmids. When discarding this outlier, the
 193 evolution rate decrease over time became significant ($p = 0.028$).

194 This trend was also observed at the individual scale within the largest RCI serie (RCI2), with four
195 relapses): most of the overtime-conserved SNPs occurred early, often between the iRCI and the first
196 rRCI. Afterwards, a dynamic of SNP emergence and clearance was observed, as shown in Fig 5B.

197 **Growth in AUM did not discriminate RCIs from SCIs**

198 The growth of 72 isolates was evaluated in rich medium (lysogenic broth [LB]) and in artificial urinary
199 medium (AUM). These isolates included 10 RCI pairs (10 iRCIs and their corresponding 10 last rRCIs),
200 35 SCIs and 17 singletons isolates (isolates responsible for a single infection in patients with recurrent
201 cystitis) (Fig 1). The mean doubling times of the four groups (iRCI, rRCI, SCI and singletons) were
202 similar in LB ($G_{iRCI} = 22.9 \pm 1.25\text{min}$, $G_{rRCI} = 23.2 \pm 1.79\text{min}$, $G_{SCI} = 23.0 \pm 1.49\text{min}$ and $G_{Singleton} = 23.6$
203 $\pm 1.99\text{min}$; $p=0.215$) and not statistically different from those of the reference strains UTI89 and K12
204 ($G_{UTI89} = 23.7 \pm 1.25\text{min}$ and $G_{K12} = 23.2 \pm 0.97\text{min}$) (Fig 6A). In AUM, all isolates grew significantly
205 slower ($p < 0.01$) than in LB ($G_{iRCI} = 43.6 \pm 3.50\text{min}$, $G_{rRCI} = 43.6 \pm 2.18\text{min}$, $G_{SCI} = 46.2 \pm 4.24\text{min}$
206 and $G_{Singleton} = 47.9 \pm 6.34\text{min}$) (Fig. 6B). Even if intra-group variability was higher in AUM than in LB,
207 no significant differences were observed between groups and *E. coli* UTI89 in AUM ($G_{UTI89-AUM} = 43.3$
208 $\pm 2.53\text{min}$). However, the laboratory strain *E. coli* K12, grew significantly slower than the other isolates
209 ($G_{K12-AUM} = 96.6 \pm 11.6\text{min}$, $p < 0.01$) (Fig 6B). Furthermore, we observed only one significant growth
210 rate increase in RCI2 pairs that could not be link to a particular genomic evolution (Fig S2).

211 Even though the mean doubling times in each medium were not significantly different between groups,
212 some isolates exhibited higher or lower growth rate than the rest of their group (represented as outliers
213 on Fig 6), with no association with specific genomic characteristics identified.

214 **RCIs and SCIs exhibited similar biofilm formation capacity**

215 To evaluate whether biofilm production could be a specific trait associated with recurrence, we studied
216 the biofilm formation capacity of 72 isolates in LB and in AUM. Globally, all groups tested exhibited
217 low levels of biofilm formation in LB ($A_{590\text{nm}} < 1$) and even lower levels in AUM ($A_{590\text{nm}} < 0.4$). No
218 significant differences in biofilm production were observed between groups and the positive control *E.*

219 *coli* K12, neither in LB nor in AUM (Fig 7). Furthermore, no significant evolution in biofilm production
220 was observed for RCI pairs, neither in LB nor in AUM (Fig S3).

221 Of note, the overtime missense mutation identified in the PNAG biosynthesis associated poly-beta-1,6-
222 N-acetyl-D-glucosamine synthase in rRCI_2681 (from the RCI1 series), did not lead to a significant
223 difference in biofilm formation capacity compared to its corresponding iRCI_2630.

224 **Invasion of bladder epithelial cells was similar between iRCIs and** 225 **SCIs**

226 To determine whether bladder epithelial cell (BEC) invasion was a common feature among RCIs,
227 invasion capacity of 60 isolates (10 iRCIs and their corresponding last rRCIs, 24 SCIs and 16 singletons)
228 was evaluated by gentamicin protection assay (Fig 8). Globally, the invasion rates observed were very
229 low (between 0.0005 and 0.1194%). Eight out of the 50 isolates (16.0%) exhibited similar or greater
230 invasion capacity than the positive control strain UTI89 (Fig 8). The presence of intracellular bacteria
231 was confirmed for 4 strains by fluorescence microscopy (Fig 9). There was no correlation between
232 invasion capacity and recurrence, since the eight invasive isolates included two singleton isolates and
233 six SCIs. Of note, the invasion rate was significantly increased between 2 iRCIs and rRCIs (RCI5b and
234 RCI9, Fig S4). Surprisingly, *E. coli* str. K12 invasion rate was similar to that of *E. coli* UTI89.

235 **Discussion**

236 Our study firstly aimed to identify *E. coli* genomic and/or phenotypic characteristics associated with
237 UTI recurrence. To this end, we compared 24 RCIs to 24 phylogenetically paired SCIs. This pairing
238 aimed to reduce bias due to genetic background differences and was based on CH typing, a powerful
239 and cost-effective tool to predict MLST results and investigate UPEC [10,11] .

240 Previous studies could not identify a specific combination of presence/absence of virulence factor genes
241 as predictive marker of rUTI [17,18]. However, Ejrnaes *et al.* carried out a comparative study on 78
242 UPEC isolates causing persistence or relapse of UTI and 77 isolates followed by cure or reinfection.
243 They reported that rUTI-associated isolates exhibit a higher aggregate virulence score, associated with
244 12 significantly more prevalent virulence factor genes [17]. In contrast, this study showed no difference

245 in virulence score or VFD prevalence between groups. However, our approaches were different, Ejnraes
246 *et al.* having worked on a larger but unpaired collection [17]. Since no difference in VFD prevalence
247 was observed, we also studied gene polymorphism. Various levels of polymorphism were observed, but
248 without association with recurrence. The most polymorphic genes mainly encoded adhesins and iron
249 acquisition systems, both being already described as key virulence factors for UTI establishment [12].
250 This polymorphism might have a wide range of effects on bacterial phenotype, such as gene silencing,
251 overexpression, substrate affinity modification. Such polymorphism could be the result of a host-
252 specific adaptation. Indeed, Zdziarski *et al.* showed that the urinary tract inoculation of a single
253 asymptomatic bacteriuria strain of *E. coli* in six patients led to genomic changes resulting in unique
254 adaptation patterns in each patient [23].

255 In a recent comparative genomic analysis of 45 recurrent and 43 non-recurrent *E. coli* urinary isolates,
256 Nielsen *et al.* did not identify any significantly associated genetic factors [18]. Unlike this study, a lower
257 abundance of MGEs was observed in our RCI group. Of note, 8 SCIs and 2 RCIs had a prophage
258 integrated between genes encoding an envelope stress response system involved in regulation of
259 virulence in UPEC (*cpx* operon) and an iron efflux system (*fieF*) [24,25]. However, any effect of
260 prophage presence was observed on growth or biofilm formation under iron limitation. The only 2 genes
261 significantly more prevalent in SCIs derived from this prophage.

262 When exploring MGEs abundance, we observed that large contigs containing *tra* operon genes were
263 present in SCIs but absent in paired iRCI, suggesting that it corresponded to plasmids, but even more
264 interesting, plasmid curation events were also observed across intra-patient relapse series. This
265 confirmed a result obtained by Thänert *et al.* [19], profiling the within-host adaptation of 119 lineages
266 of UPEC sampled longitudinally from both the gastrointestinal and urinary tracts of 123 patients with
267 UTI. Indeed, Thänert *et al.* observed that rUTI-associated isolates exhibited lower MGE richness,
268 suggesting that MGE loss constitute a common UPEC adaptation to the urinary tract. By contrast, SCIs
269 maintained their fitness in multiple habitats partly thanks to the conservation of their MGEs [19].

270 In 2021, Nielsen *et al.* showed that recurrence-associated UPECs might adapt to the urinary tract through
271 SNP accumulation, mainly in genes involved in diverse metabolic pathways which were over-

272 represented among the mutated genes [18]. Our results highlighted that genes affected by nsSNPs were
273 mostly involved in various metabolic pathways (37.9%). However, this should be taken carefully since
274 the analysis was performed on the only few mutated proteins (58 out of 160) for which a functional
275 pathway could successfully be attributed. Moreover, metabolism genes representing approximately
276 30% of the coding *E. coli* genome [26], their representation among the mutated genes of our study was
277 not significantly higher than expected ($p = 0.2$).

278 Interestingly, genes involved in environmental information processing, and more specifically ABC
279 transporters, were the second most represented functional category of genes with nsSNPs emerging in
280 our RCI series. These ABC transporters were mainly involved in transport of important compounds for
281 UPEC growth in urine: diverse ionic compounds (including iron, nickel and phosphate), carbohydrates
282 and peptides [27]. Interestingly, some of the mutated genes encoding transporters were already identified
283 as critical factors for UPEC adaptation, such as *envZ* (response to osmolarity and pH variations) [28] or
284 *fecC* (iron transport) [29]. Such mutations combined with those affecting metabolism genes might
285 constitute a specific adaptation to human urine composition.

286 No pathoadaptative genes [30] were observed in this study, probably because of the great inter-
287 individual diversity of human urine composition [31]. Each isolate may specifically adapt its
288 metabolism to its host, rather than all isolates broadly sharing the same adaptation to urine. This host-
289 shaped adaptation could occur early in relapse series. Indeed, we observed that RCI evolution rate
290 significantly decreased over the course of relapses. Moreover, overtime-conserved SNPs – which
291 possibly represent adaptative SNPs - mostly occurred early, between the iRCI and the first rRCI.

292 Plasmid loss also occurred early in the course of relapses as highlighted by our data. Taken together,
293 these results suggest that RCIs rapidly adapt to the urinary tract followed by a slower phase of micro-
294 adaptation. However, it should be noted that the main limitation of our approach was the lack of
295 information concerning the UTI history of the patients before inclusion. Very early adaptation events
296 may have occurred before the iRCI sampling, leading to a possible underestimation of this early
297 adaptation phenomenon.

298 One of the main characteristics of UPECs is their ability to efficiently grow in urine [27]. To our
299 knowledge, our work is the first to assess the growth capacity of such a large isolate collection in AUM.
300 This medium was initially described by Brooks and Keevil in 1997 and designed to reproduce the
301 physicochemical conditions (osmolarity, pH...) encountered in urine [32] to study growth of various
302 uropathogens including *E. coli* [33]. The main advantages of this medium compared to the pooled human
303 urine are its reproducibility and its stability [32,34]. The higher mean doubling time observed for our
304 clinical isolates in AUM ($G = 45.8$ min) than that described for UPEC in pooled human urine (between
305 36.3 and 40.5min) [34,35] can be explained by the greater complexity of human urine, which contains
306 more usable substrates (carbohydrates, amino acids...) than the AUM that only contains small amounts
307 of peptone and yeast extract [31,32].

308 Although no difference in mean doubling time was observed between RCIs and SCIs, we found a notable
309 within-group diversity, that cannot be explained by the genomic profiles of the isolates. However, as
310 genomic data did not highlight any common pattern but suggested that isolates might adapt specifically
311 to conditions encountered in their host, the use of AUM might not be able to reveal the physiological
312 changes following such specific adaptations. Moreover, such *in vitro* experiments do not mimic the
313 immune pressure existing *in vivo*. Further studies should then focus on characterizing RCI growth in
314 their host's urine to determine whether genomic events identified in RCIs constitute a specific adaptation
315 to the patient's urine composition.

316 Biofilm has long been known to promote persistent infection in patients [36]. To date, the association
317 of biofilm formation with recurrent UPEC UTI is controversial [17,37]. Most studies described biofilm
318 formation in minimal media, as nutrient stress appears to be an important factor for *E. coli* biofilm
319 induction [38]. For example, Soto *et al.* observed a positive correlation between biofilm production and
320 recurrence in a minimal medium supplemented with LB [37]. Nevertheless, Ejrnaes *et al.* found no
321 correlation between biofilm formation and recurrence using AB medium, a minimal medium containing
322 0.2% glucose and 0.5% of casamino acids [17]. In comparison to these media, AUM induces a more
323 intense starvation. However, like in our fitness experiments, no significant differences of biofilm
324 production were observed between RCIs and SCIs of this study, confirming the results obtained by

325 Erjnaes *et al.* [17]. Yet, our comparison between relapsing and sporadic strains was limited by the rate
326 of biofilm production which was very low overall. This low production of biofilm can be explained by
327 the slower growth of isolates in AUM and could affect the quality of the results, due to the sensitivity
328 of the detection method. As other studies have suggested that combination of mechanical and biological
329 stresses encountered in urinary tract triggers biofilm formation [38,39], it would interesting to perform
330 biofilm formation assays in dynamic models that better mimic urine flux.

331 BEC invasion by UPECs is considered as one of the main mechanisms explaining relapses [14–16].
332 Since its discovery, this mechanism was extensively studied in murine UTI models using the reference
333 cystitis-causing strain UTI89 [40–42]. Data concerning clinical isolates are lacking. Using a
334 monolayered cell infection experiments which allowed to study the formation of intracellular bacterial
335 communities (IBCs) [43], we found that massive internalization of clinical isolates was a rare but
336 existing phenomenon. Most RCI and SCI invasion rates were comprised between 0.001 and 0.01%,
337 which is in the range of published data [42]. No significant correlation between relapse and invasion
338 capacity was however supported by our data, suggesting that this factor alone cannot explain the onset
339 of recurrence. However even though IBC is an important mechanism for UPEC persistence in bladder,
340 it is only part of a more complex mechanism including quiescent intracellular reservoirs (QIRs)
341 formation in transitional epithelium, which cannot be evaluated in our model. More complex models
342 such as organoids or *in vivo* experiments should be used to further investigate the role of QIR in
343 recurrence. Moreover, urothelial internalization is not the only mechanism that may promote UPEC
344 persistence. The UPEC ability to durably colonize the gastrointestinal tract and vagina has also to be
345 considered [19,44,45]. Future studies should therefore consider exploring these reservoirs through
346 longitudinal analysis of vaginal, intestinal and bladder microbiomes of patients suffering from rUTI.

347 To conclude, rather than a common adaptation mechanism to the urinary tract, our results suggest a
348 diversity of mechanisms leading to host-specific adaptation and thus to recurrence. Further studies
349 exploring host-pathogen relationships and impact of QIR formation with organoid models in rUTI
350 pathogenesis should be performed to contribute to translation of these results into innovative treatments.

351 **Material and methods**

352 **Ethics statements**

353 This study is based on an UPEC collection from an epidemiological study on community acquired UTI
354 (patients prospectively included over a 17-month period), founded by the French Ministry of Health and
355 approved by the Medical Research Ethics Committee of the Rouen University hospital (VITALE study,
356 Clinicaltrials.gov, identifier: NCT02292160). Participating patients received an information letter and
357 provided written informed consent.

358 **Bacterial isolates**

359 This study focused on 115 UPEC isolates from the VITALE collection (Fig 1). Among them, 80 were
360 isolated from patients with recurrent cystitis (*i.e.* with ≥ 2 episodes over a study period of 6 months or
361 ≥ 4 episodes over 12 months). Based on a previous comparative genomic analysis, 58 isolates were
362 involved in series of cystitis relapses (series of cystitis episodes caused by a single strain [11]) and were
363 then defined as “relapse-causing isolates (RCIs)”. The 58 RCIs corresponded to 24 strains, each with an
364 initial occurrence isolate (iRCIs) followed by up to 4 sequential relapse isolates per strain, for a total 34
365 relapse isolates (rRCIs). The remaining 22 out of the 80 isolates from patients with recurrent cystitis
366 were responsible for a single cystitis episode during the 18-months of patient follow-up and were defined
367 as “singletons” [11].

368 A control group ($n = 35$) was formed with UPEC “sporadic isolates” (SCIs) collected from patients
369 experiencing only one cystitis episode over the 17-month period of the VITALE study. The SCIs were
370 selected based on their genetic proximity with the RCIs, according to a phylogeny constructed with CH
371 typing data [11]. Briefly, each iRCI was paired with a SCI from the same CH type when possible. If not,
372 a SCI from the genetically closest CH type was used. Proximity between CH types was determined using
373 a phylogeny based on concatenated sequences of *fumC* and *fimH* [11]. A minimum spanning tree was
374 constructed with BioNumerics software (Applied Maths NV, Sint-Martens-Latem, Belgium) using the
375 unweighted pair group method with arithmetic mean (UPGMA).

376 Comparative genomic studies were performed on 48 isolates: the 24 iRCIs and 24 phylogenetically
377 paired SCIs from the 35 SCIs control group. Intra-host evolution studies were based on the 58 RCIs (24
378 iRCIs and 34 rRCIs). Phenotypic studies were performed on 77 isolates (Fig 1).

379 *E. coli* str. UTI89 and *E. coli* str. K12 were used as control strains for phenotypic experiments. *E. coli*
380 str. K12 was purchased from the Pasteur institute (CIP 106782).

381 **Whole genome sequencing and assembly**

382 Short read whole genome sequencing (WGS) and assembly were performed on SCIs and RCIs as
383 previously described [11]. Briefly, sequencing was performed on an Illumina NextSeq500 using the
384 Nextera XT library kit (Illumina Inc., San Diego, CA, USA) and assemblies were produced using
385 fq2dna v21.06 (gitlab.pasteur.fr/GIPhy/fq2dna) (Table S1).

386 Long read WGS was also performed for the initial occurrence of each RCI (iRCI). These were amplified
387 by overnight incubation in 10mL of lysogenic broth (LB, MP biomedical, Santa-Ana, USA), at 37°C
388 and under agitation. Up to 2.10^9 cells were used for genomic DNA extraction using the Dneasy Blood
389 and Tissue minikit (Qiagen, Hilden, Germany) according to the manufacturer recommendations for
390 isolating Gram-negative bacteria DNA. Alternatively, the Monarch® HMW DNA Extraction kit for
391 Tissue (New England Biolabs, Ipswich, MA, USA) was used to improve DNA fragment length. DNA
392 concentration and quality were checked using a Qubit (Thermo Fisher Scientific, Waltham, MA, USA)
393 and a Nanodrop 2000 (Thermo Fisher Scientific) instruments.

394 Up to 1µg genomic DNA was used for library preparation according to the « Native barcoding genomic
395 DNA protocol with EXP-NBD104, EXP-NBD114 and SQK-LSK109 » (ONT, Oxford, UK). Libraries
396 were sequenced using R9.4.1 flowcells on a minION Mk1B device. Real-time basecalling,
397 demultiplexing and filtering were performed using MinKNOW v21.11.8 (ONT, Oxford, UK) and
398 Guppy v5.1.13 (ONT, Oxford, UK). Quality control was then performed using Nanoplot v1.38.1 [46].

399 Short and long reads from Illumina and ONT sequencing, resp, were then used for hybrid assembly
400 using Unicycler 0.4.9. Short read assemblies from the previous study [11] and newly obtained hybrid
401 assemblies were compared using Bandage v0.8.1 [47] for visualization and BUSCO v5.2.2 [48] with

402 the enterobacterales_odb10 lineage dataset for genome completeness evaluation. Sequencing metrics
403 are available in Table S1.

404 **SCI and RCI comparative genomic study**

405 Short read assemblies of phylogenetically 24 paired iRCIs and SCIs were annotated using Prokka 1.14.5
406 [49] with defaults parameters. The protein sequences of VFDs used in the study of Ejmaes et al. [17]
407 were retrieved from the annotated genomes and compared using MEGA X [50]. A virulence score
408 corresponding to the total number of VFD for a given isolate. RCI and SCI short reads were also mapped
409 to the sequence of pUTI89 (NC_007941.1) using Snippy v4.3.6 (github.com/tseemann/snippy). More
410 than 75% coverage of the plasmid sequence was interpreted as positive match.

411 Pan-genome analysis of the 48 RCIs and SCIs was performed using Roary 3.12.0 [51]. Neighbor joining
412 tree inference was performed using MEGA X [50] based on the translated core gene alignment produced
413 by Roary. The phylogenetic tree, the core genome allele profiles obtained from the raw short reads using
414 cgMLSTFinder v1.1.5 [52,53] and the presence/absence table produced by Roary were visualized using
415 Phandango v1.3.0 [54].

416 The presence/absence table produced by Roary was also used with Scoary v1.6.16 [55] for genome wide
417 association study (GWAS), to identify the genes that were significantly associated with recurrence. The
418 protein sequences deriving from these genes were submitted to BlastKOALA [56] and Kegg Mapper
419 Reconstruct [57] to classify them according to functional pathways.

420 The 48 annotated draft genomes were visualized using Proksee [58] and searched for phage regions
421 between the *cpx* operon and *fiE* gene using Phigaro 2.3.0 [59]. Reads from each RCI were mapped to
422 its paired SCI draft genome using snippy v4.3.6 and visualized using Proksee [58] in order to explore
423 large sequences that were preferentially found in SCI genomes.

424 **Intra-patient analysis of RCI gene evolution**

425 Hybrid genome assembly of each iRCI was annotated using Prokka v1.14.5. [49] Short reads from each
426 rRCI were mapped to their respective iRCI annotated hybrid genome assembly using Snippy v4.3.6 and

427 visualized using Proksee [58] to identify potential plasmid loss over time. Lost contigs were blasted
428 (<https://blast.ncbi.nlm.nih.gov/Blast.cgi>) to identify whether they were previously described as
429 plasmids, and their gene content was analyzed.

430 Intra-patient SNP analysis was performed by mapping short reads from each rRCI to their respective
431 iRCI annotated draft genome assembly using Snippy v4.3.6. As a control, reads from each iRCI were
432 also mapped to their own annotated draft genome assembly; artefact SNPs identified this way were
433 removed from the analysis when also found in rRCIs from the same series. The genes in which SNPs
434 were identified between an iRCI and its rRCIs were listed and their sequences were submitted to
435 BlastKOALA [56] and Kegg Mapper Reconstruct [57] for functional classification.

436 For evolution rate analysis, SNP/day rates were calculated based on the number of SNPs obtained above
437 for each iRCI/rRCI pair divided by the time (days) elapsed between rRCI and iRCI sampling. Evolution
438 rate plot was constructed using Microsoft Excel (Microsoft corporation Available from:
439 <https://office.microsoft.com/excel>). Correlation between time and evolution rate was tested with
440 Spearman's rank correlation test, using R software (V 4.1.3, R Foundation, Vienna, Austria).

441 **Growth assays**

442 The artificial urinary medium (AUM) used in the phenotypic experiments was prepared as described by
443 Brooks and Keevil with minor modifications [32] (Table S4). Briefly, 100mM of 2-(N-
444 morpholino)ethanesulfonic acid (MES) was added to improve buffer capacity and limit precipitate
445 formation. Isolates were grown overnight in LB or AUM at 37°C with shaking at 150 rpm. The cultures
446 were then adjusted to optical density (OD_{600nm}) of 0.05, and 200µL of each standardized suspension was
447 transferred in triplicate in a microtiter plate. The plate was then incubated under continuous double
448 orbital shaking conditions (108 rpm) at 37°C during 24h in a microplate reader (Spark®, Tecan,
449 Männedorf, Switzerland) and OD_{600nm} was measured every 15 min. All experiments were performed at
450 least three times. The *E. coli* str. K12 substr. MG1655 (abridged *E. coli* str. K12 in the rest of the
451 manuscript) and UTI89 strains were used as internal controls and fresh medium as negative control for

452 each experiment. Statistical analyses of the growth curves were performed using R software (v 4.2.1,
453 <https://www.R-project.org/>).

454 **Biofilm assays**

455 Isolates were grown to late stationary phase in LB or AUM; overnight cultures were adjusted as
456 described above and incubated in a microplate in static conditions at 37°C for 24h. Nonadherent bacteria
457 were removed by washing with H₂O before adding crystal violet 0.5%. After 10 min of incubation under
458 gentle shaking at room temperature, the excess of dye was discarded, and each well was washed 3 times
459 with H₂O. Ethanol 95% was then added, and the plate was incubated under gentle shaking at room
460 temperature for 10 min. Absorbance at 590nm (A_{590nm}) was measured using a microplate reader. All
461 experiments were performed at least three times. The *E. coli* str. K12 strain was used as a positive control
462 and fresh medium as a negative control for each experiment. Data were expressed as percent of biofilm
463 formation relative to the positive control.

464 **Cell line and growth conditions**

465 Human bladder epithelial cell (BEC) line 5637 (ATCC HTB-9) was maintained at 37°C and 5% CO₂ in
466 RPMI 1640 media (ThermoFisher Scientific, Waltham, MA, USA) supplemented with 10% fetal bovine
467 serum and 2 mM Glutamine. Cells cultures were discarded after 20 passages.

468 **Gentamicin protection assay**

469 Bacterial isolates were grown in LB at 37°C for 48h in static conditions to promote type I pilus
470 expression [43]. Bacteria were then washed three times in phosphate buffer saline (PBS) to eliminate
471 potential secreted toxins. Bacteria were resuspended in PBS, enumerated by serial dilution on LB agar
472 plates and used as inoculum for infections (multiplicity of infection of 15). BEC cells were seeded the
473 day before infection in 12-well tissue culture plates at 1.6×10^5 cells/cm². Before infection, culture
474 medium was replaced by RPMI supplemented with 5% of fetal bovine serum. To synchronize bacterial
475 contact to host cells, plates were centrifugated at 750 rpm for 5 min at room temperature after bacterial
476 inoculation. After 2 hours of incubation at 37°C, cells were washed twice with PBS and incubated 1
477 hour at 37°C in culture medium supplemented with gentamicin (50 µg/mL) to kill extracellular bacteria.

478 Gentamicin solution was then removed and cell monolayers were washed three times with PBS before
479 being lysed in PBS-0.2% Triton-X-100 solution for 10 min at 37°C. BEC lysates were then plated on
480 LB agar plates and the number of CFUs obtained after a 24h-incubation at 37°C (corresponding to the
481 number of intracellular bacteria in the initial cell lysates) was quantified. Five replicates per isolates
482 were performed. Results were expressed as invasion percentages using the following formula:

$$483 \quad \text{Invasion percentage}(\%) = \frac{\text{Intracellular bacteria}}{\text{Inoculated bacteria}} \times 100$$

484

485 **Fluorescence microscopy**

486 BEC cells were seeded on glass slides and infected with four UPEC isolates (UTI89, rRCI_2627,
487 SCI_2259 and SCI_2263) as described above. After 3 hours of infection, cells were washed three times
488 with PBS and fixed in PBS-4% paraformaldehyde. Identification of intracellular bacteria was performed
489 thanks to a differential staining procedure [60]. Extracellular bacteria were labeled with a primary mouse
490 anti-*E. coli* antibody (1:200; Abcam, ab35654, Cambridge, UK) in PBS-1% BSA for 1 hour at room
491 temperature. Cells were then washed and labeled for 1 hour with a secondary goat anti-mouse antibody
492 Alexa Fluor 546-conjugate (1:500; Invitrogen, A-11030, Waltham, MA, USA) in PBS-1% BSA. Cells
493 were then washed with PBS and permeabilized in PBS-0.3% Triton-X-100 for 15 min at room
494 temperature. Total bacteria were labeled with the same primary antibody and a secondary goat anti-
495 mouse Alexa Fluor488-conjugate (1:500; Invitrogen, A-32723, Waltham, MA, USA). Cells were
496 labeled in parallel with Hoechst 33342 (1:1,000; ThermoFisher Scientific, H3570, Waltham, MA, USA)
497 and phalloidin conjugated to Alexa Fluor 647 (1:100; Invitrogen, A-22287, Waltham, MA, USA). Slides
498 were mounted in Fluoromount reagent (Invitrogen, Waltham, MA, USA) and images were acquired with
499 a Leica Thunder tissue 3D microscope and processed with ImageJ software [61].

500 **Statistical analyses**

501 All statistical analyses were performed using R (V 4.1.3, R Foundation, Vienna, Austria). Comparison
502 of proportions were performed using Pearson's chi-squared test when applicable. Otherwise, we used

503 Fisher's exact test for count data. Global means comparison were performed using Kruskal-Wallis rank
504 sum test and pairwise comparison were performed using Wilcoxon, Mann-Whitney test.

505 **Acknowledgements**

506 The VITALE study (NCT02292160) was funded by the French Ministry of Health (Programme
507 Hospitalier de Recherche Clinique) We are grateful to Normandy Region and Rouen University for
508 funding in part the cursus of Nicolas Vautrin.

509 We are indebted to the volunteers. We thank all the collaborators and colleagues who helped in the
510 study. We are grateful to the Genotoul bioinformatics platform Toulouse Occitanie (Bioinfo Genotoul,
511 <https://doi.org/10.15454/1.5572369328961167E12>) for providing help and computing resources.

512 **References**

- 513 1. Foxman B. Epidemiology of urinary tract infections: Incidence, morbidity, and economic costs.
514 Disease-a-Month. 2003;49: 53–70. doi:10.1067/mda.2003.7
- 515 2. Foxman B. The epidemiology of urinary tract infection. Nat Rev Urol. 2010;7: 653–660.
516 doi:10.1038/nrurol.2010.190
- 517 3. Glover M, Moreira CG, Sperandio V, Zimmern P. Recurrent urinary tract infections in healthy
518 and nonpregnant women. Urological Science. 2014;25: 1–8. doi:10.1016/j.urols.2013.11.007
- 519 4. Medina M, Castillo-Pino E. An introduction to the epidemiology and burden of urinary tract
520 infections. Therapeutic Advances in Urology. 2019;11: 175628721983217.
521 doi:10.1177/1756287219832172
- 522 5. Ejrnaes K, Sandvang D, Lundgren B, Ferry S, Holm S, Monsen T, et al. Pulsed-Field Gel
523 Electrophoresis Typing of *Escherichia coli* Strains from Samples Collected before and after
524 Pivmecillinam or Placebo Treatment of Uncomplicated Community-Acquired Urinary Tract
525 Infection in Women. J Clin Microbiol. 2006;44: 1776–1781. doi:10.1128/JCM.44.5.1776-
526 1781.2006
- 527 6. Vosti KL. A prospective, longitudinal study of the behavior of serologically classified isolates of
528 *Escherichia coli* in women with recurrent urinary tract infections. Journal of Infection. 2007;55:
529 8–18. doi:10.1016/j.jinf.2007.01.006
- 530 7. Beerepoot MAJ, Den Heijer CDJ, Penders J, Prins JM, Stobberingh EE, Geerlings SE. Predictive
531 value of *Escherichia coli* susceptibility in strains causing asymptomatic bacteriuria for women
532 with recurrent symptomatic urinary tract infections receiving prophylaxis. Clinical Microbiology
533 and Infection. 2012;18: E84–E90. doi:10.1111/j.1469-0691.2012.03773.x
- 534 8. Skjøt-Rasmussen L, Hammerum AM, Jakobsen L, Lester CH, Larsen P, Frimodt-Møller N.
535 Persisting clones of *Escherichia coli* isolates from recurrent urinary tract infection in men and
536 women. Journal of Medical Microbiology. 2011;60: 550–554. doi:10.1099/jmm.0.026963-0

- 537 9. Nemoy LL, Kotetishvili M, Tigno J, Keefer-Norris A, Harris AD, Perencevich EN, et al.
538 Multilocus Sequence Typing versus Pulsed-Field Gel Electrophoresis for Characterization of
539 Extended-Spectrum Beta-Lactamase-Producing *Escherichia coli* Isolates. *J Clin Microbiol.*
540 2005;43: 1776–1781. doi:10.1128/JCM.43.4.1776-1781.2005
- 541 10. Weissman SJ, Johnson JR, Tchesnokova V, Billig M, Dykhuizen D, Riddell K, et al. High-
542 Resolution Two-Locus Clonal Typing of Extraintestinal Pathogenic *Escherichia coli*. *Appl*
543 *Environ Microbiol.* 2012;78: 1353–1360. doi:10.1128/AEM.06663-11
- 544 11. Vautrin N, Alexandre K, Pestel-Caron M, Bernard E, Fabre R, Leoz M, et al. Contribution of
545 Antibiotic Susceptibility Testing and CH Typing Compared to Next-Generation Sequencing for
546 the Diagnosis of Recurrent Urinary Tract Infections Due to Genetically Identical *Escherichia coli*
547 Isolates: a Prospective Cohort Study of Cystitis in Women. Taneja N, editor. *Microbiol Spectr.*
548 2023; e02785-22. doi:10.1128/spectrum.02785-22
- 549 12. Lühje P, Brauner A. Virulence Factors of Uropathogenic *E. coli* and Their Interaction with the
550 Host. *Advances in Microbial Physiology.* Elsevier; 2014. pp. 337–372.
551 doi:10.1016/bs.ampbs.2014.08.006
- 552 13. Murray BO, Flores C, Williams C, Flusberg DA, Marr EE, Kwiatkowska KM, et al. Recurrent
553 Urinary Tract Infection: A Mystery in Search of Better Model Systems. *Front Cell Infect*
554 *Microbiol.* 2021;11: 691210. doi:10.3389/fcimb.2021.691210
- 555 14. Liu S, Han X, Shi M, Pang Z. Persistence of uropathogenic *Escherichia coli* in the bladders of
556 female patients with sterile urine after antibiotic therapies. *J Huazhong Univ Sci Technol [Med*
557 *Sci].* 2016;36: 710–715. doi:10.1007/s11596-016-1649-9
- 558 15. Robino L, Scavone P, Araujo L, Algorta G, Zunino P, Vignoli R. Detection of intracellular
559 bacterial communities in a child with *Escherichia coli* recurrent urinary tract infections. *Pathogens*
560 *Disease.* 2013;68: 78–81. doi:10.1111/2049-632X.12047
- 561 16. Robino L, Scavone P, Araujo L, Algorta G, Zunino P, Pérez MC, et al. Intracellular Bacteria in the
562 Pathogenesis of *Escherichia coli* Urinary Tract Infection in Children. *Clinical Infectious Diseases.*
563 2014;59: e158–e164. doi:10.1093/cid/ciu634
- 564 17. Ejrnæs K, Stegger M, Reisner A, Ferry S, Monsen T, Holm SE, et al. Characteristics of
565 *Escherichia coli* causing persistence or relapse of urinary tract infections: Phylogenetic groups,
566 virulence factors and biofilm formation. *Virulence.* 2011;2: 528–537. doi:10.4161/viru.2.6.18189
- 567 18. Nielsen KL, Stegger M, Kiil K, Lilje B, Ejrnæs K, Leihof RF, et al. *Escherichia coli* Causing
568 Recurrent Urinary Tract Infections: Comparison to Non-Recurrent Isolates and Genomic
569 Adaptation in Recurrent Infections. *Microorganisms.* 2021;9: 1416.
570 doi:10.3390/microorganisms9071416
- 571 19. Thänert R, Choi J, Reske KA, Hink T, Thänert A, Wallace MA, et al. Persisting uropathogenic
572 *Escherichia coli* lineages show signatures of niche-specific within-host adaptation mediated by
573 mobile genetic elements. *Cell Host & Microbe.* 2022;30: 1034-1047.e6.
574 doi:10.1016/j.chom.2022.04.008
- 575 20. Johnson JR, Stell AL, Kaster N, Fasching C, O’Bryan TT. Novel Molecular Variants of Allele I
576 of the *Escherichia coli* P Fimbrial Adhesin Gene *papG*. O’Brien AD, editor. *Infect Immun.*
577 2001;69: 2318–2327. doi:10.1128/IAI.69.4.2318-2327.2001

- 578 21. Manning SD, Zhang L, Foxman B, Spindler A, Tallman P, Marrs CF. Prevalence of Known P-
579 Fimbrial G Alleles in *Escherichia coli* and Identification of a New Adhesin Class. Clin Diagn Lab
580 Immunol. 2001;8: 637–640. doi:10.1128/CDLI.8.3.637-640.2001
- 581 22. Cusumano CK, Hung CS, Chen SL, Hultgren SJ. Virulence Plasmid Harbored by Uropathogenic
582 *Escherichia coli* Functions in Acute Stages of Pathogenesis. Infect Immun. 2010;78: 1457–1467.
583 doi:10.1128/IAI.01260-09
- 584 23. Zdziarski J, Brzuszkiewicz E, Wullt B, Liesegang H, Biran D, Voigt B, et al. Host Imprints on
585 Bacterial Genomes—Rapid, Divergent Evolution in Individual Patients. Guttman DS, editor.
586 PLoS Pathog. 2010;6: e1001078. doi:10.1371/journal.ppat.1001078
- 587 24. Grass G, Otto M, Fricke B, Haney CJ, Rensing C, Nies DH, et al. FieF (YiiP) from *Escherichia*
588 *coli* mediates decreased cellular accumulation of iron and relieves iron stress. Arch Microbiol.
589 2005;183: 9–18. doi:10.1007/s00203-004-0739-4
- 590 25. Debnath I, Norton JP, Barber AE, Ott EM, Dhakal BK, Kulesus RR, et al. The Cpx Stress
591 Response System Potentiates the Fitness and Virulence of Uropathogenic *Escherichia coli*. Payne
592 SM, editor. Infect Immun. 2013;81: 1450–1459. doi:10.1128/IAI.01213-12
- 593 26. Wagner A. Metabolic Networks and Their Evolution. In: Soyer OS, editor. Evolutionary Systems
594 Biology. New York, NY: Springer New York; 2012. pp. 29–52. doi:10.1007/978-1-4614-3567-
595 9_2
- 596 27. Reitzer L, Zimmern P. Rapid Growth and Metabolism of Uropathogenic *Escherichia coli* in
597 Relation to Urine Composition. Clin Microbiol Rev. 2019;33: e00101-19.
598 doi:10.1128/CMR.00101-19
- 599 28. Schwan WR. Survival of uropathogenic *Escherichia coli* in the murine urinary tract is dependent
600 on OmpR. Microbiology. 2009;155: 1832–1839. doi:10.1099/mic.0.026187-0
- 601 29. Frick-Cheng AE, Sintsova A, Smith SN, Pirani A, Snitkin ES, Mobley HLT. Ferric Citrate Uptake
602 Is a Virulence Factor in Uropathogenic *Escherichia coli*. Comstock LE, editor. mBio. 2022;13:
603 e01035-22. doi:10.1128/mbio.01035-22
- 604 30. Sokurenko E. Pathoadaptive Mutations in Uropathogenic *Escherichia coli*. Microbiol Spectr.
605 2016;4. doi:10.1128/microbiolspec.UTI-0020-2015
- 606 31. Bouatra S, Aziat F, Mandal R, Guo AC, Wilson MR, Knox C, et al. The Human Urine
607 Metabolome. Dzeja P, editor. PLoS ONE. 2013;8: e73076. doi:10.1371/journal.pone.0073076
- 608 32. Brooks T, Keevil CW. A simple artificial urine for the growth of urinary pathogens. Letters in
609 Applied Microbiology. 1997;24: 203–206. doi:10.1046/j.1472-765X.1997.00378.x
- 610 33. Ipe DS, Horton E, Ulett GC. The Basics of Bacteriuria: Strategies of Microbes for Persistence in
611 Urine. Front Cell Infect Microbiol. 2016;6. doi:10.3389/fcimb.2016.00014
- 612 34. Hogins J, Fan E, Seyan Z, Kusin S, Christie AL, Zimmern PE, et al. Bacterial Growth of
613 Uropathogenic *Escherichia coli* in Pooled Urine Is Much Higher than Predicted from the Average
614 Growth in Individual Urine Samples. Prokesch BC, editor. Microbiol Spectr. 2022;10: e02016-22.
615 doi:10.1128/spectrum.02016-22
- 616 35. Forsyth VS, Armbruster CE, Smith SN, Pirani A, Springman AC, Walters MS, et al. Rapid Growth
617 of Uropathogenic *Escherichia coli* during Human Urinary Tract Infection. Miller JF, editor. mBio.
618 2018;9: e00186-18. doi:10.1128/mBio.00186-18

- 619 36. Donlan RM. Biofilm Formation: A Clinically Relevant Microbiological Process. CLIN INFECT
620 DIS. 2001;33: 1387–1392. doi:10.1086/322972
- 621 37. Soto SM, Smithson A, Horcajada JP, Martinez JA, Mensa JP, Vila J. Implication of biofilm
622 formation in the persistence of urinary tract infection caused by uropathogenic *Escherichia coli*.
623 Clinical Microbiology and Infection. 2006;12: 1034–1036. doi:10.1111/j.1469-
624 0691.2006.01543.x
- 625 38. Chu EK, Kilic O, Cho H, Groisman A, Levchenko A. Self-induced mechanical stress can trigger
626 biofilm formation in uropathogenic *Escherichia coli*. Nat Commun. 2018;9: 4087.
627 doi:10.1038/s41467-018-06552-z
- 628 39. Eberly A, Floyd K, Beebout C, Colling S, Fitzgerald M, Stratton C, et al. Biofilm Formation by
629 Uropathogenic *Escherichia coli* Is Favored under Oxygen Conditions That Mimic the Bladder
630 Environment. IJMS. 2017;18: 2077. doi:10.3390/ijms18102077
- 631 40. Mulvey MA, Schilling JD, Hultgren SJ. Establishment of a Persistent *Escherichia coli* Reservoir
632 during the Acute Phase of a Bladder Infection. O'Brien AD, editor. Infect Immun. 2001;69: 4572–
633 4579. doi:10.1128/IAI.69.7.4572-4579.2001
- 634 41. Eto DS, Sundsbak JL, Mulvey MA. Actin-gated intracellular growth and resurgence of
635 uropathogenic *Escherichia coli*. Cell Microbiol. 2006;8: 704–717. doi:10.1111/j.1462-
636 5822.2006.00691.x
- 637 42. Schwartz DJ, Chen SL, Hultgren SJ, Seed PC. Population Dynamics and Niche Distribution of
638 Uropathogenic *Escherichia coli* during Acute and Chronic Urinary Tract Infection. Payne SM,
639 editor. Infect Immun. 2011;79: 4250–4259. doi:10.1128/IAI.05339-11
- 640 43. Blango MG, Ott EM, Erman A, Veranic P, Mulvey MA. Forced Resurgence and Targeting of
641 Intracellular Uropathogenic *Escherichia coli* Reservoirs. Beloin C, editor. PLoS ONE. 2014;9:
642 e93327. doi:10.1371/journal.pone.0093327
- 643 44. Salazar AM, Neugent ML, De Nisco NJ, Mysorekar IU. Gut-bladder axis enters the stage:
644 Implication for recurrent urinary tract infections. Cell Host & Microbe. 2022;30: 1066–1069.
645 doi:10.1016/j.chom.2022.07.008
- 646 45. Worby CJ, Schreiber HL, Straub TJ, Van Dijk LR, Bronson RA, Olson BS, et al. Longitudinal
647 multi-omics analyses link gut microbiome dysbiosis with recurrent urinary tract infections in
648 women. Nat Microbiol. 2022;7: 630–639. doi:10.1038/s41564-022-01107-x
- 649 46. De Coster W, Rademakers R. NanoPack2: population-scale evaluation of long-read sequencing
650 data. Alkan C, editor. Bioinformatics. 2023;39: btad311. doi:10.1093/bioinformatics/btad311
- 651 47. Wick RR, Schultz MB, Zobel J, Holt KE. Bandage: interactive visualization of *de novo* genome
652 assemblies. Bioinformatics. 2015;31: 3350–3352. doi:10.1093/bioinformatics/btv383
- 653 48. Manni M, Berkeley MR, Seppey M, Simão FA, Zdobnov EM. BUSCO Update: Novel and
654 Streamlined Workflows along with Broader and Deeper Phylogenetic Coverage for Scoring of
655 Eukaryotic, Prokaryotic, and Viral Genomes. Kelley J, editor. Molecular Biology and Evolution.
656 2021;38: 4647–4654. doi:10.1093/molbev/msab199
- 657 49. Seemann T. Prokka: rapid prokaryotic genome annotation. Bioinformatics. 2014;30: 2068–2069.
658 doi:10.1093/bioinformatics/btu153

- 659 50. Kumar S, Stecher G, Li M, Knyaz C, Tamura K. MEGA X: Molecular Evolutionary Genetics
660 Analysis across Computing Platforms. Battistuzzi FU, editor. *Molecular Biology and Evolution*.
661 2018;35: 1547–1549. doi:10.1093/molbev/msy096
- 662 51. Page AJ, Cummins CA, Hunt M, Wong VK, Reuter S, Holden MTG, et al. Roary: rapid large-
663 scale prokaryote pan genome analysis. *Bioinformatics*. 2015;31: 3691–3693.
664 doi:10.1093/bioinformatics/btv421
- 665 52. Clausen PTL, Aarestrup FM, Lund O. Rapid and precise alignment of raw reads against
666 redundant databases with KMA. *BMC Bioinformatics*. 2018;19: 307. doi:10.1186/s12859-018-
667 2336-6
- 668 53. Jolley KA, Maiden MC. BIGSdb: Scalable analysis of bacterial genome variation at the population
669 level. *BMC Bioinformatics*. 2010;11: 595. doi:10.1186/1471-2105-11-595
- 670 54. Hadfield J, Croucher NJ, Goater RJ, Abudahab K, Aanensen DM, Harris SR. Phandango: an
671 interactive viewer for bacterial population genomics. Kelso J, editor. *Bioinformatics*. 2018;34:
672 292–293. doi:10.1093/bioinformatics/btx610
- 673 55. Brynildsrud O, Bohlin J, Scheffer L, Eldholm V. Rapid scoring of genes in microbial pan-genome-
674 wide association studies with Scoary. *Genome Biol*. 2016;17: 238. doi:10.1186/s13059-016-1108-
675 8
- 676 56. Kanehisa M, Sato Y, Morishima K. BlastKOALA and GhostKOALA: KEGG Tools for Functional
677 Characterization of Genome and Metagenome Sequences. *Journal of Molecular Biology*.
678 2016;428: 726–731. doi:10.1016/j.jmb.2015.11.006
- 679 57. Kanehisa M, Sato Y, Kawashima M. KEGG mapping tools for uncovering hidden features in
680 biological data. *Protein Science*. 2022;31: 47–53. doi:10.1002/pro.4172
- 681 58. Grant JR, Enns E, Marinier E, Mandal A, Herman EK, Chen C, et al. Proksee: in-depth
682 characterization and visualization of bacterial genomes. *Nucleic Acids Research*. 2023;51: W484–
683 W492. doi:10.1093/nar/gkad326
- 684 59. Starikova EV, Tikhonova PO, Prianichnikov NA, Rands CM, Zdobnov EM, Ilina EN, et al.
685 Phigaro: high-throughput prophage sequence annotation. Valencia A, editor. *Bioinformatics*.
686 2020;36: 3882–3884. doi:10.1093/bioinformatics/btaa250
- 687 60. Kühbacher A, Cossart P, Pizarro-Cerdá J. Internalization assays for *Listeria monocytogenes*.
688 *Methods Mol Biol*. 2014;1157: 167–178. doi:10.1007/978-1-4939-0703-8_14
- 689 61. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. *Nat*
690 *Methods*. 2012;9: 671–675. doi:10.1038/nmeth.2089

691

692 **Figures**

693 **Fig 1. Isolate and workflow description.** RC patients = patients with recurrent cystitis, iRCI = initial
694 recurrent cystitis isolate, rRCI = recurrent cystitis isolate associated with relapse(s), SCI = sporadic
695 cystitis isolate.

696 **Fig 2. Principal component analysis based on the detection of virulence factor genes.** Red dots
697 represent iRCIs (initial recurrent cystitis isolates) and blue triangles represent SCIs (sporadic cystitis
698 isolates).

699 **Fig 3. Core genome analysis of the 24 iRCIs and their 24 CH type paired SCIs.** iRCIs = initial
700 recurrent cystitis isolates, SCIs = sporadic cystitis isolates. **A.** Neighbor-Joining phylogenetic tree based
701 on the 48 strains' translated core gene alignment (2,755,382 amino acid positions). **B.** Color-coded CH
702 type, prophage presence (purple = absent, yellow = present), clinical context of recurrence (purple =
703 iRCI, yellow = SCI) for the 48 strains. **C.** Presence/absence (blue/white) of the 15,682 genes from the
704 pan genome in each strain, sorted by gene frequency among the 48 strains. The first 2,864 genes on the
705 left represent the core genome.

706 **Fig 4. Examples of mobile genetic elements that are found in SCIs but not in their paired iRCIs**
707 **(A and B) or lost in sequential relapses in RCI patients (C).** Contigs from genome assemblies are
708 shown in an alternance of dark and light grey arrows, iRCIs = initial recurrent cystitis isolates, rRCI =
709 recurrent cystitis isolate associated with relapse(s), SCIs = sporadic cystitis isolates. Just above and
710 below, blue arrows indicate the location and orientation of CDSs on the contigs. **A.** A 40 kb portion of
711 SCI_2737 contig #6 is represented in dark grey. Orange and red arrows respectively indicate SCI-
712 associated genes Sgene1 and Sgene2. Beneath, the regions covered by the reads from paired iRCI_2003
713 are indicated in green. The >30 kb SCI_2737 genome region that is not covered by iRCI_2003 reads
714 includes 44 phage proteins similar to those from Peduovirus P24B2 (AccNum NC_049387). **B.**
715 SCI_2823 contig #59 is represented in light grey. Pink arrows indicate the location of plasmid-specific
716 genes from the *tra* operon. The reads from paired iRCI_2359 map to SCI_2823 contigs #58 and #60,
717 but not to the >30 kb contig #59, which derives from a plasmid similar to the *Escherichia coli* strain
718 HS13-1 plasmid pHS13-1-IncF (AccNum CP026494) **C.** Contig #3 from hybrid genome assembly of

719 iRCI_2359 is indicated in dark grey. Below, the coverage of this contig by the reads of the
720 corresponding rRCIs is shown in shades of green. iRCI_2359 contig #3 corresponds to a 42kb plasmid
721 similar to the *E. coli* pRHB15-C18_3, (AccMum CP057780.1) that is lost in the first to third relapses.

722 **Fig 5. Intra patient micro-evolution of RCIs by SNP acquisition.** RCIs = recurrent cystitis isolates
723 **A.** Global representation of the evolution rates (SNPs per day) from the 24 series of intra-patient RCIs
724 depending on the time elapsed between the first occurrence and the relapse (days). An outlier is circled
725 in red. The black dotted curve represents the non-significant trend when including all the dots ($p =$
726 0.124). The red curve represents the significant trend when excluding the outlier ($p = 0.028$). **B.**
727 Individual representation of the core SNPs observed over time in the largest intra-patient RCI serie
728 (RCI2). SNPs are color-coded depending of the time of emergence (the darker, the latter). CHR = Contig
729 on which the SNP was identified, POS = position of the SNP on the contig.

730 **Fig 6. Boxplots representing the doubling time (in min) of each group of isolates in lysogenic broth**
731 **(LB) (A) or in artificial urinary medium (AUM) (B).** iRCIs = initial recurrent cystitis isolates, rRCI
732 = recurrent cystitis isolate associated with relapse(s), SCIs = sporadic cystitis isolates, K12 = *E. coli str.*
733 K12. Each dot represents a mean doubling time for one isolate in the corresponding group. Red asterisks
734 represent extreme phenotypes for a given group (outliers).

735 **Fig 7. Biofilm formation in lysogenic broth (LB) (A) and in artificial urinary medium (AUM) (B)**
736 **expressed as a ratio of *E. coli str. K12* biofilm production. .** iRCIs = initial recurrent cystitis isolates,
737 rRCI = recurrent cystitis isolate associated with relapse(s), SCIs = sporadic cystitis isolates. The blue
738 dashed line represents the biofilm production level of *E. coli str. K12*. Each dot represents a mean ratio
739 of biofilm production for one isolate in the corresponding group. Red asterisks represent extreme
740 phenotypes for a given group (outliers).

741 **Fig 8. Invasion capacity of UPEC isolates in HTB-9 bladder epithelial cells after gentamicin**
742 **protection assay.** Boxplots represent the individual invasion rates of 10 iRCIs (initial recurrent cystitis
743 isolates, red), 16 singletons (pink), 24 SCIs (sporadic cystitis isolates, blue), *E. coli str. K12* (K12, green)
744 and positive control strain UTI89 (purple). Red asterisks represent outliers. Diamonds indicates isolates

745 for which microscopy results are presented in Fig 8. Blue dashed lines represent the invasion rate interval
746 described by Schwartz et al. (2011).

747 **Fig 9. Observation of intracellular bacteria (SCI_2263, reference strain UTI89) in HTB-9 bladder**
748 **epithelial cells by fluorescence microscopy.** **A.** Extracellular bacteria are labelled in red (staining
749 without cell membrane permeabilization). **B.** Total (*i.e.* intra + extracellular) bacteria are labeled in green
750 (staining with cell permeabilization). **C.** BEC nuclei are labelled with DAPI (in blue) and actin with
751 phalloidin (in purple). Extracellular bacteria are labelled in red or yellow (green + red) and intracellular
752 bacteria are labelled strictly in green. White arrows and insets are focusing on strictly intracellular
753 bacteria while grey arrows and insets on strictly extracellular bacteria.

754 **Supporting informations**

755 **Fig S1. Distribution of allelic variants of 23 virulence factor determinants in RCI and SCI groups.**
756 Each color represents an allelic variant of the corresponding gene.

757 **Fig S2. Comparison of iRCI (red) and last rRCI (orange) doubling times in two media: lysogenic**
758 **broth (LB) and artificial urinary medium (AUM).** Red asterisks represent outliers. Black asterisk
759 represents significant median doubling time differences between iRCI and rRCI ($p < 0.05$).

760 **Fig S3. Comparison of iRCI (red) and last rRCI (orange) biofilm formation in two media:**
761 **lysogenic broth (LB) and artificial urinary medium (AUM).** Red asterisks represent outliers. Black
762 asterisk represents significant median biofilm formation differences between iRCI and rRCI ($p < 0.05$).

763 **Fig S4. Comparison of invasion rate of bladder epithelial cells by iRCI (red) and last rRCI**
764 **(orange) in a given relapse series.** Names of relapse series are indicated above each boxplot. Red
765 asterisks represent outliers. Black asterisks represent significant median biofilm formation differences
766 between iRCI and rRCI ($p < 0.05$).

767 **Table S1. Sequencing, typing and pairing data for 85 isolates included in the study**

768 **Table S2. List and gene annotation of the 7 lost plasmids in 5 RCI series**

769 **Table S3. List and functional annotation of the 13 overtime conserved SNPs identified in 6 isolates**
770 **from 6 RCI series**

771 **Table S4. Composition of AUM adapted from Brooks and Keevil (1997)**

772




Figure 1




Figure 2




Figure 3




Figure 4




Figure 5A

B

RCI2 serie (Ref : 2287 relapses : [1] = 2329, [2] = 2378, [3] = 2442, [4] = 2526)						
CHR	POS	Day 0	Day 29	Day 48	Day 100	Day 145
contig_00008	8791	A	T	T	T	T
contig_00009	88296	C	T	T	C	C
contig_00013	58748	C	A	C	C	C
contig_00042	22792	T	G	G	G	G
contig_00046	28378	G	G	G	G	A
contig_00108	336	T	T	G	T	T

Figure 5B





Figure 6A

B**Figure 6B**

A





Figure 7A

B**Figure 7B**




Figure 8




Figure 9